Abstract
Classic “BCR-ABL1-negative” MPN is an operational sub-category of MPN that includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) harboring JAK2V617F as the most common mutation. JAK2V617F can be detected in about 95 % of patients with PV while remaining 5 % of PV patients carry a somatic mutation of JAK2 exon 12. Approximately one-third of patients with ET or PMF do not carry any mutation in JAK2 or MPL. In December 2013, mutations were described in calreticulin (CALR) gene in 67–71 and 56–88 % of JAK2V617F and MPL negative patients with ET and PMF, respectively. Since this discovery CALR mutations have been reported to be mutually exclusive with JAK2V617F or MPL mutations. However recently few studies (eleven published reports) reported the coexistence of JAK2V617F and CALR in MPN. In the present study we are reporting JAK2V617F positive ET patient from our center with coexisting CALR exon 9 mutation type c.1214_1225del12 (p.E405_D408del) that was never reported before as a coexisting mutation and describing in detail the clinical outcomes.
This is a preview of subscription content, log in via an institution to check access.
References
Luo W, Yu Z (2015) Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs). Stem Cell Investig. doi:10.3978/j.issn.2306-9759.2015.08.01
Lundberg P, Karow A, Nienhold R et al (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123:2220–2228
Lin Y, Liu E, Sun Q et al (2015) The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Path 144:165–171
Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of Calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390
Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405
Chi J, Nicolaou KA, Nicolaidou V et al (2014) Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia 28:1152–1154
Tafferi A, Pardanani A (2014) CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol 11:125–126
Guglielmelli P, Nangalia J, Green AR, Vannucchi M (2014) CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Am J Hematol 89:453–456
Tefferi A, Thiele J, Vannucchi AM et al (2014) An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 28:1407–1413
Park SH, Kim SY, Lee SM et al (2014) Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of single tertiary hospital in Korea. Ann Lab Med 35:233–237
Machado-Neto JA, de Melo Campos P, de Albuquerque DM et al (2015) Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. Rev Bras Hemat Hemot 37:211–214
Tefferi A, Lasho TL, Finke CM et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28:1472–1477
Broséus J, Lippert E, Harutyunyan AS et al (2014) Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 28:1374–1376
Fu R, Xuan M, Zhou Y et al (2014) Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia 28:1912–1914
McGaffin G, Harper K, Stirling D, McLintock L (2014) JAK2V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol 167:276–278
Xu N, Ding L, Yin C et al (2015) A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients. Ann Hematol 94:865–867
Shirane S, Araki M, Morishita S et al (2015) JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica 100:e46–e48
Ha JS, Kim YK (2015) Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med 35:22–27
Zamora L, Xicoy B, Cabezón M et al (2015) Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis. Leuk Lym 11:1–2
Lim KH, Chang YC, Gon-Shen Chen C et al (2015) Frequent CALR exon 9 alterations in JAK2V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer J 5:e295
Al Assaf C, Van Obbergh F, Billiet J et al (2015) Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica 100:893–897
Tefferi A, Lasho TL, Tischer A et al (2014) The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 124:2465–2466
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in this were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from the participant included in this study.
Additional information
Munazza Rashid and Rifat Zubair Ahmed contributed equally to this study and should be considered as co-first authors.
Rights and permissions
About this article
Cite this article
Rashid, M., Ahmed, R.Z., Ahmed, S. et al. Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. Indian J Hematol Blood Transfus 32 (Suppl 1), 112–116 (2016). https://doi.org/10.1007/s12288-016-0658-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-016-0658-y